International
Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Estonia
Hungary
Latvia
Lithuania
Kosovo
North Macedonia
Poland
Romania
Serbia
Slovakia
Slovenia
Switzerland (German)
Switzerland (French)
Razvoj poslovanja
Mediji
Upoznajte nas
Zaposlenje
Kontaktirajte nas
NAŠ PORTFOLIO
Lekovi
Proizvodi bez recepta
Partneri & Brendovi
Preporuke partnera i potrošača
O kompaniji Ewopharma
Vizija/Misija
Naše vrednosti
Naša strategija
Liderstvo
Korporativna odgovornost
Teritorija
Razvoj poslovanja
Mediji
Upoznajte nas
Zaposlenje
Kontaktirajte nas
International
Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Estonia
Hungary
Latvia
Lithuania
Kosovo
North Macedonia
Poland
Romania
Serbia
Slovakia
Slovenia
Switzerland (German)
Switzerland (French)
Mediji
SAOPŠTENJA ZA JAVNOST
1
2
3
4
Next
29.05.2026
Ewopharma and Dr. Falk Pharma renew their long-standing partnership - a commitment built to last
Pročitaj više
15.04.2026
Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage Ⅲ NSCLC
Pročitaj više
26.02.2026
BioGaia AB extends long-standing distribution partnership with Ewopharma
Pročitaj više
16.12.2025
Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication
Pročitaj više
26.07.2024
European Commission Approves Sugemalimab
Pročitaj više
1
2
3
4
Next
![[Translate to Serbia:]](/fileadmin/user_upload/Ewopharma_CStone_Sugemalimab_01.png "[Translate to Serbia:]")
